Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto legal cases in the country. In March 2014, the South African Advertising Standards Authority (ASA) upheld a complaint, made by the African Centre for Biosafety, that Monsanto had made "unsubstantiated" claims about genetically modified crops in its radio advertisements, and ordered that these adverts be pulled. In March 2015 after considering further documentation from Monsanto, the ASA reversed its ruling. Monsanto legal cases Monsanto has been involved in several high-profile lawsuits, as both plaintiff and defendant. It has been defendant in a number of lawsuits over health and environmental issues related to its products. Monsanto has also made frequent use of the